An Interview with Professor Patrik Brundin

Related Articles:

• An Interview with Professor Patrik Brundin January 15, 2019 Prof. Patrik Brundin leads the Center for Neurodegenerative Science at Van Andel Research Institute where his research team is focused on experimental models and novel therapies in Parkinson’s disease. Prof. Brundin is one of the most cited scientists in neurodegenerative diseases, with a focus on Parkinson’s, and has received numerous awards for his work. He is the co-editor-in-chief of the…
• Diabetes Drug Slows Experimental Parkinson’s Disease Progression. July 17, 2017 GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease (PD) following publication of research findings today in the journal Science Translational Medicine. “We hope this will be a watershed moment for millions of…
• Diabetes Drug Slows Experimental Parkinson’s Disease Progression. July 17, 2017 GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease (PD) following publication of research findings today in the journal Science Translational Medicine. “We hope this will be a watershed moment for millions of…
• Diabetes Drug Slows Experimental Parkinson’s Disease Progression. July 17, 2017 GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease (PD) following publication of research findings today in the journal Science Translational Medicine. “We hope this will be a watershed moment for millions of…
• Diabetes Drug Slows Experimental Parkinson’s Disease Progression. July 17, 2017 GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease (PD) following publication of research findings today in the journal Science Translational Medicine. “We hope this will be a watershed moment for millions of…
• Diabetes Drug Slows Experimental Parkinson’s Disease Progression. July 17, 2017 GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease (PD) following publication of research findings today in the journal Science Translational Medicine. “We hope this will be a watershed moment for millions of…
• Diabetes Drug Slows Experimental Parkinson’s Disease Progression. July 17, 2017 GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease (PD) following publication of research findings today in the journal Science Translational Medicine. “We hope this will be a watershed moment for millions of…
• Diabetes Drug Slows Experimental Parkinson’s Disease Progression. July 17, 2017 GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease (PD) following publication of research findings today in the journal Science Translational Medicine. “We hope this will be a watershed moment for millions of…
• Diabetes Drug Slows Experimental Parkinson’s Disease Progression. July 17, 2017 GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease (PD) following publication of research findings today in the journal Science Translational Medicine. “We hope this will be a watershed moment for millions of…
• Rallying to the Challenge 2017 - survey results presented October 17, 2017 Leading Parkinson’s experts and advocates from around the world gathered at Van Andel Research Institute (VARI) in Grand Rapids for 'Grand Challenges in Parkinson’s Disease', a scientific event highlighting the latest breakthroughs in Parkinson’s research and treatment. The 6th annual symposium included talks from 19 scientific speakers, a poster session and extensive networking opportunities. See more here. “Bringing together scientists, physicians…
• Rallying to the Challenge 2017 - survey results presented October 17, 2017 Leading Parkinson’s experts and advocates from around the world gathered at Van Andel Research Institute (VARI) in Grand Rapids for 'Grand Challenges in Parkinson’s Disease', a scientific event highlighting the latest breakthroughs in Parkinson’s research and treatment. The 6th annual symposium included talks from 19 scientific speakers, a poster session and extensive networking opportunities. See more here. “Bringing together scientists, physicians…
• Rallying to the Challenge 2017 - survey results presented October 17, 2017 Leading Parkinson’s experts and advocates from around the world gathered at Van Andel Research Institute (VARI) in Grand Rapids for 'Grand Challenges in Parkinson’s Disease', a scientific event highlighting the latest breakthroughs in Parkinson’s research and treatment. The 6th annual symposium included talks from 19 scientific speakers, a poster session and extensive networking opportunities. See more here. “Bringing together scientists, physicians…
• Promising Respiratory Drug Focus of New Trial for Parkinson's August 8, 2017 The trial is the latest to be launched as part of the Linked Clinical Trials (LCT) initiative, a programme spearheaded by The Cure Parkinson’s Trust in collaboration with Van Andel Research Institute (VARI), Michigan, USA, with funding from VARI and the John Black Charitable Foundation. “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or…
• Promising Respiratory Drug Focus of New Trial for Parkinson's August 8, 2017 The trial is the latest to be launched as part of the Linked Clinical Trials (LCT) initiative, a programme spearheaded by The Cure Parkinson’s Trust in collaboration with Van Andel Research Institute (VARI), Michigan, USA, with funding from VARI and the John Black Charitable Foundation. “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or…
• Promising Respiratory Drug Focus of New Trial for Parkinson's August 8, 2017 The trial is the latest to be launched as part of the Linked Clinical Trials (LCT) initiative, a programme spearheaded by The Cure Parkinson’s Trust in collaboration with Van Andel Research Institute (VARI), Michigan, USA, with funding from VARI and the John Black Charitable Foundation. “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or…
• Promising Respiratory Drug Focus of New Trial for Parkinson's August 8, 2017 The trial is the latest to be launched as part of the Linked Clinical Trials (LCT) initiative, a programme spearheaded by The Cure Parkinson’s Trust in collaboration with Van Andel Research Institute (VARI), Michigan, USA, with funding from VARI and the John Black Charitable Foundation. “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or…
• Promising Respiratory Drug Focus of New Trial for Parkinson's August 8, 2017 The trial is the latest to be launched as part of the Linked Clinical Trials (LCT) initiative, a programme spearheaded by The Cure Parkinson’s Trust in collaboration with Van Andel Research Institute (VARI), Michigan, USA, with funding from VARI and the John Black Charitable Foundation. “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or…
• Promising Respiratory Drug Focus of New Trial for Parkinson's August 8, 2017 The trial is the latest to be launched as part of the Linked Clinical Trials (LCT) initiative, a programme spearheaded by The Cure Parkinson’s Trust in collaboration with Van Andel Research Institute (VARI), Michigan, USA, with funding from VARI and the John Black Charitable Foundation. “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or…
• Promising Respiratory Drug Focus of New Trial for Parkinson's August 8, 2017 The trial is the latest to be launched as part of the Linked Clinical Trials (LCT) initiative, a programme spearheaded by The Cure Parkinson’s Trust in collaboration with Van Andel Research Institute (VARI), Michigan, USA, with funding from VARI and the John Black Charitable Foundation. “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or…
• Promising Respiratory Drug Focus of New Trial for Parkinson's August 8, 2017 The trial is the latest to be launched as part of the Linked Clinical Trials (LCT) initiative, a programme spearheaded by The Cure Parkinson’s Trust in collaboration with Van Andel Research Institute (VARI), Michigan, USA, with funding from VARI and the John Black Charitable Foundation. “With this trial, we’re moving beyond treating Parkinson’s symptoms. We want to actually slow or…